The activated MEK/ERK and AKT/mTOR signaling pathways have been found to increase Mcl-1 levels in AML cells [40-42] such that Mcl-1 is being considered as a therapeutic target for AML therapy [42]. The gene discussed is MCL1; the disease is acute myeloid leukemia.